Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96GP6

UPID:
SREC2_HUMAN

ALTERNATIVE NAMES:
SRECRP-1; Scavenger receptor expressed by endothelial cells 2 protein

ALTERNATIVE UPACC:
Q96GP6; E5RFB8; Q58A83; Q8IXF3; Q9BW74

BACKGROUND:
The Scavenger receptor class F member 2, also known as SRECRP-1 or Scavenger receptor expressed by endothelial cells 2 protein, mediates crucial cellular interactions. Its role extends beyond the poor mediation of Ac-LDL binding and degradation, suggesting a complex function in cellular adhesion and signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Linked to Van den Ende-Gupta syndrome through genetic variants, the study of Scavenger receptor class F member 2 offers a promising avenue for therapeutic intervention. The exploration of its functions and mechanisms could lead to novel treatments for patients suffering from this syndrome.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.